Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy

Condition:   Metastatic Breast CancerIntervention:   Drug: LapatinibSponsors:   Dartmouth-Hitchcock Medical Center;   University of Colorado, Denver;   North Shore University HospitalTerminated - verified August 2013
Source: - Category: Research Source Type: clinical trials

Related Links:

DNA changes in a common type of breast cancer cell may be linked to hormone therapy resistance, according to a study published inNature Communications.Science Daily
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
ConclusionIn the neoadjuvant setting, the pCR rate with the standard TCbHP  →  T-DM1+P regimen was numerically better than the TCbHP regimen alone and significantly better in patients with ER+. Personalization of the T-DM1+P regimen could serve as a reasonable approach to minimize toxicity while maintaining efficacy.Trial registration ID: UMIN-CTR: UMIN000014649.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsDisease progression occurred intracranially more often than extracranially following resection of a solitary BCBM. In ER+ patients, postoperative hormonal therapy was associated with longer OS. Postoperative HER2-targeted therapy did not show survival benefit in HER2+ patients. These results should be validated in larger cohorts.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurposeGiven that 27-hydroxycholesterol (27HC) is the first identified endogenous selective estrogen receptor modulator, the aim of this study was to investigate the extent to which dietary or lifestyle factors impact circulating 27HC concentrations in a large-scale setting.MethodsThis cross-sectional analysis included 1,036 women aged 35 –65 years who served as controls in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heidelberg breast cancer case–control study. Circulating 27HC was quantified in serum using liquid chromatography/tandem mass spectrometry. Generalized line...
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
Hormone therapy is an effective and non-toxic therapy for oestrogen and progesterone receptor-positive breast cancer and for prostate cancer. Serum concentrations of oestradiol and testosterone are controlled by the hypothalamic-pituitary-gonadal pathway. Oestradiol is produced in premenopausal women from the ovaries, and in postmenopausal women by peripheral conversion of adrenal androgens by aromatase. In premenopausal women with breast cancer and men with prostate cancer, treatment is primarily achieved by castration.
Source: Medicine - Category: Internal Medicine Authors: Tags: Systemic therapy Source Type: research
CONCLUSIONS: Compared to women with no history of thyroid disorder, hypothyroidism was associated with a lower risk of breast cancer. This was mainly seen among those who received thyroid replacement therapy and had never used menopausal hormone therapy. Among the treatment options for hypothyroidism, levothyroxine had the strongest inverse association with breast cancer risk. PMID: 31918623 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
Authors: Yin Z, Warner JL, Malin BA Abstract Hormonal therapy is an effective yet challenging long-term treatment for patients with hormone receptor positive breast cancer. Understanding what factors indicate discontinuation of a recommended hormonal therapy medication can help improve treatment experience. To date, studies on medication discontinuation have focused on patient information gathered through questionnaires, structured electronic medical records and online discussion boards. However, there has been little investigation into the communications between healthcare providers, which may provide additional i...
Source: AMIA Annual Symposium Proceedings - Category: Bioinformatics Tags: AMIA Annu Symp Proc Source Type: research
Publication date: February 2020Source: Pharmacological Research, Volume 152Author(s): Zhen Xu, Cuiui Liu, Qian Zhao, Jinhui Lü, Xin Ding, An Luo, Jia He, Guangxue Wang, Yuan Li, Zhaoqing Cai, Zhongrui Wang, Junjun Liu, Suling Liu, Wenshu Li, Zuoren YuAbstractTriple-negative breast cancers (TNBC) are more aggressive due to lacking receptors for hormone therapy and maintaining stemness features in cancer cells. Herein we found long non-coding RNA CCAT2 overexpressed specially in TNBC, and in breast cancer stem cells (BCSC) as well. Enforced overexpression and targeted knockdown demonstrated the oncogenic function of CCA...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
We present the case of a 63-year-old patient that was diagnosed in another Clinic with squamous skin carcinoma, but, after complete resection in our Hospital, it was proven to be breast cancer. At diagnosis, computed tomography (CT) scan showed local disease. Adjuvant treatment, consisting in chemotherapy and radiotherapy, was administered. At the beginning of hormonal therapy, the patient had a new CT scan that showed liver and bone metastases. The patient started palliative hormonal treatment with bisphosphonates. The aim of the study was to highlight both the importance of early diagnosis and treatment and the aggressiv...
Source: Romanian Journal of Morphology and Embryology - Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research
Breast cancer survivors who underwent chemotherapy or hormone therapy were found to be more likely to have a higher symptom burden and lower overall sense of well-being than noncancer counterparts.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Research